| __timestamp | Amphastar Pharmaceuticals, Inc. | Incyte Corporation |
|---|---|---|
| Wednesday, January 1, 2014 | 28427000 | 347523000 |
| Thursday, January 1, 2015 | 37065000 | 479514000 |
| Friday, January 1, 2016 | 41199000 | 581861000 |
| Sunday, January 1, 2017 | 43415000 | 1326361000 |
| Monday, January 1, 2018 | 57564000 | 1197957000 |
| Tuesday, January 1, 2019 | 68853000 | 1154111000 |
| Wednesday, January 1, 2020 | 67229000 | 2215942000 |
| Friday, January 1, 2021 | 60932000 | 1458179000 |
| Saturday, January 1, 2022 | 74771000 | 1585936000 |
| Sunday, January 1, 2023 | 73741000 | 1627594000 |
| Monday, January 1, 2024 | 2606848000 |
In pursuit of knowledge
In the competitive world of biopharmaceuticals, research and development (R&D) spending is a key indicator of a company's commitment to innovation. Over the past decade, Incyte Corporation and Amphastar Pharmaceuticals, Inc. have demonstrated contrasting approaches to R&D investment. From 2014 to 2023, Incyte's R&D expenses surged by over 360%, peaking in 2020 with a remarkable $2.2 billion. This aggressive investment strategy underscores Incyte's dedication to pioneering new treatments and maintaining a competitive edge.
Conversely, Amphastar Pharmaceuticals has shown a more conservative growth in R&D spending, with a 160% increase over the same period. By 2023, Amphastar's R&D expenses reached approximately $74 million, reflecting a steady yet cautious approach to innovation. This divergence in spending strategies highlights the varied paths companies take in the pursuit of pharmaceutical advancements, each tailored to their unique market positions and strategic goals.
Who Prioritizes Innovation? R&D Spending Compared for Zoetis Inc. and Amphastar Pharmaceuticals, Inc.
Comparing Innovation Spending: Biogen Inc. and Incyte Corporation
Research and Development: Comparing Key Metrics for Incyte Corporation and Lantheus Holdings, Inc.
Incyte Corporation vs Perrigo Company plc: Strategic Focus on R&D Spending
Incyte Corporation vs Agios Pharmaceuticals, Inc.: Strategic Focus on R&D Spending
Incyte Corporation vs Mesoblast Limited: Strategic Focus on R&D Spending
Comparing Innovation Spending: Incyte Corporation and Iovance Biotherapeutics, Inc.
Research and Development Expenses Breakdown: Intra-Cellular Therapies, Inc. vs Amphastar Pharmaceuticals, Inc.
R&D Insights: How Grifols, S.A. and Amphastar Pharmaceuticals, Inc. Allocate Funds
Corcept Therapeutics Incorporated or Amphastar Pharmaceuticals, Inc.: Who Invests More in Innovation?
Comparing Innovation Spending: Rhythm Pharmaceuticals, Inc. and Amphastar Pharmaceuticals, Inc.
Protagonist Therapeutics, Inc. or Amphastar Pharmaceuticals, Inc.: Who Invests More in Innovation?